Lilly presents new oncology data at AACR annual meeting

Lilly has unveiled data on four of its key developmental oncology molecules at the American Association for Cancer Research (AACR) annual meeting in Washington DC.

The studies presented at the event demonstrated the potential of the CDK4/6 inhibitor LY2835219 in treating a wide range of cancers, including non-small cell lung cancer, melanoma, mantle cell lymphoma and ovarian cancer, as well as the showcasing the versatility of the IgG4 monoclonal antibody LY2875358.

Further data shared at the AACR meeting illustrated the possible uses of the MET small molecule LY2801653 and TGF-beta inhibitor LY2157299 both as single-agent tailored therapies and as combination treatments.

Dr Richard Gaynor, vice-president of product development and medical affairs for Lilly Oncology, said: "We believe that our research is going to position Lilly at the forefront of the next decade of cancer research."

Earlier this year, Lilly revealed data from a global survey on World Cancer Day showing that people across the globe wish to see more investment and faster access to new cancer treatments.